keyword
MENU ▼
Read by QxMD icon Read
search

Octreotide

keyword
https://www.readbyqxmd.com/read/28526153/pharmacology-of-octreotide-clinical-implications-for-anesthesiologists-and-associated-risks
#1
REVIEW
Reza M Borna, Jonathan S Jahr, Susanna Kmiecik, Ken F Mancuso, Alan D Kaye
Many patients presenting with a history of foregut, midgut neuroendocrine tumors (NETs) or carcinoid syndrome can experience life-threatening carcinoid crises during anesthesia or surgery. Clinicians should understand the pharmacology of octreotide and appreciate the use of continuous infusions of high-dose octreotide, which can minimize intraoperative carcinoid crises. We administer a prophylactic 500-μg bolus of octreotide intravenously (IV) and begin a continuous infusion of 500 μg/h for all NET patients...
June 2017: Anesthesiology Clinics
https://www.readbyqxmd.com/read/28507839/issues-in-managing-hurthle-cell-carcinoma-of-thyroid-a-case-report
#2
Patricia Tai, Martin Korzeniowski, Evgeny Sadikov, Kurian Joseph, Angus Kirby, Jon Tonita, Aamer Mahmud
A 61-year-old woman noticed a right neck lump in October 2001. Fine needle aspiration showed follicular neoplasm, adenoma versus carcinoma. The ultrasound scan showed a solid mass of maximum dimension of 3.7 cm. She had a right thyroid lobectomy and isthmectomy in January 2002 (first surgery). The tissue specimen showed a 4.5 cm Hurthle cell carcinoma (HCC) with vascular invasion. There were no capsular invasion, extra-thyroidal extension, or margin involvement. A completion left lobectomy (second surgery) was performed two weeks later...
April 14, 2017: Curēus
https://www.readbyqxmd.com/read/28507564/management-of-the-hormonal-syndrome-of-neuroendocrine-tumors
#3
Paweł Gut, Joanna Waligórska-Stachura, Agata Czarnywojtek, Nadia Sawicka-Gutaj, Maciej Bączyk, Katarzyna Ziemnicka, Jakub Fischbach, Kosma Woliński, Jarosław Kaznowski, Elżbieta Wrotkowska, Marek Ruchała
Gastroenteropancreatic neuroendocrine tumors (GEP/NET) are unusual and rare neoplasms that present many clinical challenges. They characteristically synthesize store and secrete a variety of peptides and neuroamines which can lead to the development of distinct clinical syndrome, however many are clinically silent until late presentation with mass effects. Management strategies include surgery cure and cytoreduction with the use of somatostatin analogues. Somatostatin have a broad range of biological actions that include inhibition of exocrine and endocrine secretions, gut motility, cell proliferation, cell survival and angiogenesis...
April 1, 2017: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/28503791/blood-glucose-and-insulin-concentrations-after-octreotide-administration-in-horses-with-insulin-dysregulation
#4
N Frank, P Hermida, A Sanchez-Londoño, R Singh, C M Gradil, C K Uricchio
BACKGROUND: Octreotide is a somatostatin analog that suppresses insulin secretion. HYPOTHESIS: We hypothesized that octreotide would suppress insulin concentrations in horses and that normal (N) horses and those with insulin dysregulation (ID) would differ significantly in their plasma glucose and insulin responses to administration of octreotide. ANIMALS: Twelve horses, N = 5, ID = 7. METHODS: Prospective study. An oral sugar test was performed to assign horses to N and ID groups...
May 15, 2017: Journal of Veterinary Internal Medicine
https://www.readbyqxmd.com/read/28500831/somatotropinomas-inadequately-controlled-with-octreotide-may-over-respond-to-pasireotide-the-importance-of-dose-adjustment-to-achieve-long-term-biochemical-control
#5
Ilan Shimon, Wolfgang Saeger, Luiz Eduardo Wildemberg, Monica R Gadelha
OBJECTIVE: To present two female patients with acromegaly inadequately controlled with long-acting octreotide who were subsequently treated with the multireceptor-targeted somatostatin analogue pasireotide that over-suppressed IGF-1 levels. METHODS: We report two patients who failed surgery and received long-acting octreotide 20-30 mg/month as part of two double-blind, Phase III clinical trials. After 6-12 months of octreotide treatment, both patients remained inadequately controlled and were switched to long-acting pasireotide 40 mg/month as part of a crossover extension phase...
January 2017: Hormones: International Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28489125/severe-hypoproteinemia-as-a-harbinger-of-m%C3%A3-n%C3%A3-trier-s-disease-in-autoimmune-pancreatitis
#6
Julio Maria Fonseca Chebli, Liliana Andrade Chebli, Tarsila Campanha da Rocha Ribeiro, Pedro Duarte Gaburri
Ménétrier's disease is an extremely rare disease of unknown etiology causing gastric mucosal hypertrophy and protein-losing gastropathy. Rare cases of this condition have been reported in patients with autoimmune diseases. However, to the best of our knowledge, Ménétrier's disease associated with autoimmune pancreatitis (AIP) has never been reported. We described a case of severe hypoproteinemia as a harbinger of Ménétrier's disease associated with AIP. The patient was successfully treated with octreotide and high-protein diet, which led to symptomatic remission and significant improvement in serum levels of albumin and recovery of the nutritional status...
March 2017: Revista da Associação Médica Brasileira
https://www.readbyqxmd.com/read/28488730/octreotide-associated-neutropenia
#7
Stacy S Tse, Troy Kish
Drug-induced neutropenia and agranulocytosis are rare adverse events but can be fatal. Neutropenia can be induced by a myriad of drugs from almost every pharmacologic class. Octreotide is a somatostatin analogue that has been used to treat variceal bleeding, acromegaly, and severe diarrhea associated with metastatic tumors, and to reduce symptoms in the setting of malignant bowel obstruction and pseudo-obstruction. The most common adverse effects associated with octreotide include pain at the injection site and gastrointestinal effects such as loose stools, cramping, and nausea; neutropenia is not currently listed as an adverse effect of the drug...
May 10, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28482555/octreotide-conjugated-fluorescent-pegylated-polymeric-nanogel-for-theranostic-applications
#8
Vineeth M Vijayan, Sachin J Shenoy, Jayabalalan Muthu
Targeted nanocarriers can significantly increase the efficiency of therapeutic formulations by ensuring the site specific delivery of the cargo. Here in, we report a novel actively targeted fluorescent nanogel, PMB-OctN, based on photoluminescent comacromer [PEG-maleic acid-4 aminobenzoic acid], diethylene glycoldimethacrylate and octreotide. The nanogel has spherical morphology with average particle size around 40nm. The PMB-OctN can load 78% of anticancer drug and release for 5days and beyond in a sustained way...
July 1, 2017: Materials Science & Engineering. C, Materials for Biological Applications
https://www.readbyqxmd.com/read/28471845/early-efficacy-of-and-toxicity-from-lutetium-177-dotatate-treatment-in-patients-with-progressive-metastatic-net
#9
Deborah Pencharz, Martin Walker, Mehmet Yalchin, Ann-Marie Quigley, Martyn Caplin, Christos Toumpanakis, Shaunak Navalkissoor
OBJECTIVE: Lutetium-177 DOTA-D-Phe1-Tyr3-octreotide (Lu-DOTATATE) is a treatment option for patients with well-differentiated metastatic neuroendocrine tumours. Our centre started administering this therapy in 2012. The aim of this study was therefore to analyse the first cohort of patients treated with Lu-DOTATATE to determine its early efficacy and toxicity. PATIENTS AND METHODS: We retrospectively analysed patient, tumour and treatment characteristics, end-of-treatment outcome, time to progression and toxicity in 79 consecutive patients treated with Lu-DOTATATE who had progressive NET according to Response Evaluation Criteria in Solid Tumours criteria...
May 3, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28466888/somatostatin-receptor-targeted-organometallic-iridium-iii-complexes-as-novel-theranostic-agents
#10
Vojtech Novohradsky, Ana Zamora, Albert Gandioso, Viktor Brabec, José Ruiz, Vicente Marchán
A novel somatostatin receptor-targeted anticancer agent based on the conjugation of a highly cytotoxic and luminescent cyclometalated iridium(iii) complex to tumor-targeting vectors based on octreotide peptide has been described, and its potential for targeted theranostic applications has been demonstrated.
May 3, 2017: Chemical Communications: Chem Comm
https://www.readbyqxmd.com/read/28459498/octreotide-is-ineffective-in-treating-tumor-induced-osteomalacia-results-of-a-short-term-therapy
#11
Diana Ovejero, Diala El-Maouche, Beth A Brillante, Azar Khosravi, Rachel I Gafni, Michael T Collins
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome in which unregulated hypersecretion of fibroblast growth factor 23 (FGF23) by phosphaturic mesenchymal tumors (PMT) causes renal phosphate wasting, hypophosphatemia, and osteomalacia. The resulting mineral homeostasis abnormalities and skeletal manifestations can be reversed with surgical resection of the tumor. Unfortunately, PMTs are often difficult to locate, and medical treatment with oral phosphate and vitamin D analogues is either insufficient to manage the disease or not tolerated...
April 29, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28458907/hypersecretion-of-acth-and-prl-from-pituitary-adenoma-in-men1-adequately-managed-by-medical-therapy
#12
Shinsuke Uraki, Hiroyuki Ariyasu, Asako Doi, Hiroto Furuta, Masahiro Nishi, Takeshi Usui, Hiroki Yamaue, Takashi Akamizu
SUMMARY: A 54-year-old man had gastrinoma, parathyroid hyperplasia and pituitary tumor. His family history indicated that he might have multiple endocrine neoplasia type 1 (MEN1). MEN1 gene analysis revealed a heterozygous germline mutation (Gly156Arg). Therefore, we diagnosed him with MEN1. Endocrinological tests revealed that his serum prolactin (PRL) and plasma adrenocorticotropic hormone (ACTH) levels were elevated to 1699 ng/mL and 125 pg/mL respectively. Immunohistochemical analysis of the resected pancreatic tumors revealed that the tumors did not express ACTH...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28458896/octreotide-therapy-and-restricted-fetal-growth-pregnancy-in-familial-hyperinsulinemic-hypoglycemia
#13
Marianne Geilswijk, Lise Lotte Andersen, Morten Frost, Klaus Brusgaard, Henning Beck-Nielsen, Anja Lisbeth Frederiksen, Dorte Møller Jensen
SUMMARY: Hypoglycemia during pregnancy can have serious health implications for both mother and fetus. Although not generally recommended in pregnancy, synthetic somatostatin analogues are used for the management of blood glucose levels in expectant hyperinsulinemic mothers. Recent reports suggest that octreotide treatment in pregnancy, as well as hypoglycemia in itself, may pose a risk of fetal growth restriction. During pregnancy, management of blood glucose levels in familial hyperinsulinemic hypoglycemia thus forms a medical dilemma...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28454406/carcinoid-syndrome-from-a-carcinoid-tumor-of-the-pancreas-without-liver-metastases-a-case-report-and-literature-review
#14
Nikolaos Zavras, Demetrios Schizas, Nikolaos Machairas, Vasileia Damaskou, Nikolaos Economopoulos, Anastasios Machairas
A carcinoid tumor of the pancreas (CTP) is a rare pancreatic neoplasm, and usually presents with carcinoid syndrome (CS). CS consists of the classic symptom triad of cutaneous flushing, diarrhea and valvular disease, and occurs in the majority of patients with liver metastases. In the present study, the patient presented with symptoms of CS. A diagnosis of CTP with CS was suspected due to high levels of urine 5-hydroxyindolacetic acid, and this was confirmed by a fine-needle aspiration biopsy. Computed tomography showed extended lymphadenopathy, but no liver metastases...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28454229/somatostatin-receptor-expression-indicates-improved-prognosis-in-gastroenteropancreatic-neuroendocrine-neoplasm-and-octreotide-long-acting-release-is-effective-and-safe-in-chinese-patients-with-advanced-gastroenteropancreatic-neuroendocrine-tumors
#15
Yuhong Wang, Wei Wang, Kaizhou Jin, Cheng Fang, Yuan Lin, Ling Xue, Shiting Feng, Zhiwei Zhou, Chenghao Shao, Minhu Chen, Xianjun Yu, Jie Chen
Gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) is known to overexpress somatostatin receptors (SSTRs), most commonly SSTR2 and SSTR5. The expression of SSTRs on tumor cells forms the basis for somatostatin analog treatment of patients with NEN. The present study detected the expression of SSTR2 and SSTR5 in GEP-NEN and investigated the efficacy and safety of octreotide long-acting release (LAR) in the treatment of advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) in China. The present study reported that functionality of the pancreas, G1 and G2 grading, NET classification and Tumor-Node-Metastasis stages I and II were associated with higher SSTR2 positive expression...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28454119/anti-proliferative-and-anti-secretory-effects-of-everolimus-on-human-pancreatic-neuroendocrine-tumors-primary-cultures-is-there-any-benefit-from-combination-with-somatostatin-analogs
#16
Amira Mohamed, David Romano, Alexandru Saveanu, Catherine Roche, Manuela Albertelli, Federica Barbieri, Thierry Brue, Patricia Niccoli, Jean-Robert Delpero, Stephane Garcia, Diego Ferone, Tullio Florio, Vincent Moutardier, Flora Poizat, Anne Barlier, Corinne Gerard
Therapeutic management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is challenging. The mammalian target of rapamycin (mTOR) inhibitor everolimus recently obtained approval from the Food and Drug Administration for the treatment of patients with advanced pancreatic neuroendocrine tumors (pNETs). Despite its promising antitumor efficacy observed in cell lines, clinical benefit for patients is unsatisfactory. The limited therapeutic potential of everolimus in cancer cells has been attributed to Akt activation due to feedback loops relief following mTOR inhibition...
April 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28452797/a-national-survey-of-computed-tomography-doses-in-hybrid-pet-ct-and-spect-ct-examinations-in-the-uk
#17
Gareth R Iball, Natalie A Bebbington, Maria Burniston, Sue Edyvean, Louise Fraser, Peter Julyan, Nasreen Parkar, Tim Wood
OBJECTIVES: The aim of this study was to conduct a nationwide survey of computed tomography (CT) doses for a wide range of PET-CT and single photon emission computed tomography-computed tomography (SPECT-CT) imaging procedures, with the aim of generating proposed UK national diagnostic reference levels (NDRLs). METHODS: CT protocol and dosimetry data for three PET-CT and seven SPECT-CT examinations were gathered from centres across the UK. Data were divided according to CT purpose (attenuation correction, localization or diagnostic) and third quartile values of scanner average dose metrics were used to generate suggested NDRLs for a range of examination and CT purpose combinations...
June 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28446479/severe-chronic-diarrhoea-secondary-to-primary-lymph-node-gastrinoma
#18
Mouhanna Abu Ghanimeh, Khalil Abuamr, Esmat Sadeddin, Osama Yousef
The existence of primary lymph node (LN) gastrinoma is questionable and controversial. In fact, the presence of gastrinoma in such uncommon site raises the possibility of metastasis from another occult primary site. An extensive evaluation and careful follow-up is always warranted. A female aged 48 years presented with chronic abdominal pain and watery diarrhoea. Her serum gastrin and chromogranin were elevated, and an underlying gastrinoma was suspected. Further evaluation with an octreotide scan, an endoscopic ultrasound and a secretin stimulation test confirmed the diagnosis...
April 26, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28444114/efficacy-of-everolimus-plus-octreotide-lar-in-patients-with-advanced-neuroendocrine-tumor-and-carcinoid-syndrome-final-overall-survival-from-the-randomized-placebo-controlled-phase-3-radiant-2-study
#19
M E Pavel, E Baudin, K E Öberg, J D Hainsworth, M Voi, N Rouyrre, M Peeters, D J Gross, J C Yao
Background: In the phase 3 RADIANT-2 study, everolimus plus octreotide long-acting repeatable (LAR) showed improvement of 5.1 months in median progression-free survival vs placebo plus octreotide LAR among patients with advanced neuroendocrine tumors associated with carcinoid syndrome. The progression-free survival P-value was marginally above the prespecified threshold for statistical significance. Here, we report final overall survival (OS) and key safety update from RADIANT-2. Patients and methods: The RADIANT-2 trial compared everolimus (10 mg/day, orally; n= 216) vs placebo ( n= 213), both in conjunction with octreotide LAR (30 mg, intramuscularly, every 28 days)...
April 24, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28439221/congenital-hyperinsulinism-caused-by-a-de-novo-mutation-in-the-abcc8-gene-a-case-report
#20
Zsuzsanna Molnár, Lfdia Balogh, János Kappelmayer, László Madar, Éva Gombos, István Balogh
Congenital hyperinsulinism (CHI) is a rare genetic disorder characterized by inappropriate insulin secretion and severe hypoglycaemia. There are two histological subtypes: diffuse and focal form. Diffuse form is most common in autosomal recessive mutations in ABCC8/KCNJ11 gene, while focal CHI is caused a paternally inherited mutation and a somatic maternal allele loss. Here we report a case of a term male infant presented with severe hyperinsulinaemic hypoglycaemia. Gene panel testing was performed to give rapid genetic diagnosis...
March 2017: EJIFCC
keyword
keyword
8581
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"